DOPTELET
LOE Approachingavatrombopag maleate
NDAORALTABLETPriority Review
Approved
May 2018
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
DOPTELET (avatrombopag maleate) is bioavailable, small molecule tpo receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. First approved in 2018.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DOPTELET (avatrombopag maleate) is an oral, small molecule thrombopoietin (TPO) receptor agonist approved in 2018 for treating thrombocytopenia in adult patients with chronic liver disease and chronic immune thrombocytopenia (ITP), as well as pediatric ITP patients aged 1 year and older. The drug stimulates megakaryocyte proliferation and platelet production without competing with endogenous TPO, providing an additive effect on platelet generation. It competes in the TPO agonist class alongside established agents like eltrombopag (PROMACTA) and newer agents like lusutrombopag (MULPLETA), offering an oral dosing option for patients requiring platelet support.
$0.1BPart D
1.2 years to LOEMechanism of Action
bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
Started Feb 2022
199 enrolled
Immune ThrombocytopeniaITP
Why This Matters for Your Career
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.